新闻+
重要活动

我们很高兴与所有利益相关者进行有效沟通,通过新闻资讯更新本公司及产品研发进展。

新闻

AnHeart and Innovent Announce Interim Data from Phase Ⅱ Trial (TRUST) of Taletrectinib in ROS1-Positive NSCLC at the CSCO 2021 Annual Meeting

In the crizotinib treatment-naïve patient group (n=21), the confirmed objective response rate (ORR) was 90.5% (19/21) and the disease control rate (DCR) was 90.5% (19/21). …

AnHeart Therapeutics Announces Formation of Scientific Advisory Board

New York, NY/Hangzhou China – September 22, 2021 —  AnHeart Therapeutics (“AnHeart”), a clinical-stage global biopharmaceutical company committed to developing novel cancer therapies, announced today …

Taletrectinib用于 NTRK融合实体瘤二期篮式试验首例病人给药

Hangzhou, Suzhou China/New York, USA– June 17, 2021 – AnHeart Therapeutics Co., Ltd. (“AnHeart”), a clinical stage oncology company focused on underserved patients in global …

葆元医药和信达生物在2021 ASCO会议上报告Taletrectinib用于ROS1融合阳性非小细胞肺癌的二期试验初步结果

Hangzhou, China June 7/New York June 6, 2021 – AnHeart Therapeutics Co., Ltd (“AnHeart”), a clinical stage oncology company focused on underserved patients in global …

葆元医药和信达生物宣布达成Taletrectinib在大中华地区的独家许可协议

Hangzhou, Suzhou China/New York June 1st, 2021 – AnHeart Therapeutics Co., Ltd. (“AnHeart”), a clinical stage oncology company focused on underserved patients in global markets, …

葆元医药宣布将在2021 ASCO会议上报告Taletrectinib用于ROS1阳性非小细胞肺癌的临床二期试验初步结果

Hangzhou, China/New York May 19, 2021 – AnHeart Therapeutics, Co., Ltd. (“AnHeart”), a clinical stage oncology company focused on underserved patients in global markets, announces …

针对ROS1阳性非小细胞肺癌,葆元医药发表taletrectinib的两项临床1期研究数据

Progression-Free Survival of 29.1 months reported in ROS1 TKI treatment-naïve patients and 14.1 months in patients pre-treated with one prior ROS1 TKI Hangzhou, China/New York …

葆元医药从第一三共引进两个临床阶段肿瘤药物

Expanding Oncology Pipeline to Three Novel Molecules Following its Series A+ Financing Round   Hangzhou, China/New York – September 7, 2020 – AnHeart Therapeutics, Co., …

葆元医药宣布达成A+轮股权融资协议

Proceeds to be Used for Advancing Taletrectinib Phase 2 Trials and Expanding Oncology Portfolio Hangzhou, China/New York – August 10, 2020 – AnHeart Therapeutics, Co., …

治疗非小细胞肺癌!葆元医药ROS1/NTRK抑制剂中国2期临床入组首例患者

Shanghai, China/New York – July 21, 2020 – AnHeart Therapeutics, Co., Ltd. (“AnHeart”), a clinical stage oncology company focused on underserved patients in global markets, …

共同开发ROS1/NTRK双靶点抑制剂,葆元医药与韩国NewG Lab达成合作!

Total of $7 million in milestone payments and royalty payments at double digit rates Hangzhou, China/New York, NY – July 15, 2020 – AnHeart Therapeutics, Co., …

葆元医药ROS1/NTRK双靶点抗癌药1期临床数据在《临床癌症研究》发表!

Hangzhou, China/New York, NY – June 26, 2020 – AnHeart Therapeutics, Co., Ltd. (“AnHeart”), a clinical stage oncology company focused on underserved patients in global markets, …

葆元医药双靶点抗癌新药获批2期临床

HANGZHOU, China, March 23, 2020 (GLOBE NEWSWIRE) — AnHeart Therapeutics, Co., Ltd. (“AnHeart”), a clinical stage oncology company focused on underserved patients in global markets, today …

葆元医药新一代ROS1/NTRK抑制剂AB-106研究成果

Research results of AnHeart’s new-generation ROS1/NTRK inhibitor AB-106 published in Nature Communications   HANGZHOU, Sept. 25 2019 /PRNewswire/ — The preclinical results of AB-106 (original …

沙利文授予葆元医药2019沙利文中国新经济—卓越科创奖

AnHeart Therapeutics Won the 2019 Sullivan China New Economy – Excellence in Innovation Award Frost & Sullivan, the world leading growth consulting company, awarded AnHeart …

葆元医药完成 1 亿元 A 轮融资,抗癌新药即将进入中国临床

On May 15, 2019, AnHeart Therapeutics (Hangzhou) Co., Ltd.. (hereinafter referred to as AnHeart) announced the completion of the series A round of financing raising …

第一三共与美国葆元生物就一款ROS1/NTRK抑制剂签署全球独家许可协议

Daiichi Sankyo Out-Licenses ROS1/NTRK Inhibitor DS-6051 to AnHeart Therapeutics   TOKYO and BASKING RIDGE, N.J. and NEW YORK, Dec. 17, 2018/PRNewswire/ — Daiichi Sankyo Company, …

重要活动